Neumic Therapeutics is developing a focused ultrasound platform that precisely controls where and when brain therapy acts, enabling both neuromodulation and targeted drug delivery. The platform is designed for patient-specific treatment planning and has demonstrated in vivo evidence of modulating neural activity and triggering targeted drug release. It targets multiple neurological disorders including tinnitus, Parkinson's disease, brain cancer, epilepsy, and stroke.
Funding
Funding not disclosed
Founders
Product
Problem
Neurological disorders such as Parkinson's disease, epilepsy, brain cancer, and stroke often require treatments that are either invasive, systemic, or imprecise, leading to significant side effects and limited efficacy. Current therapeutic approaches frequently lack the spatial and temporal precision needed to target specific brain regions while sparing healthy tissue, and patient-specific anatomical differences complicate treatment planning.
Solution
Neumic Therapeutics provides a focused ultrasound platform that enables two distinct therapeutic modalities: neuromodulation and targeted drug delivery. The platform uses precisely controlled ultrasound to modulate neural activity and trigger localized drug release at specific brain targets, offering a non-invasive alternative to traditional surgical or systemic approaches. The system is designed for patient-specific treatment planning, accounting for the fact that every brain is anatomically different. Evidence of the platform's effectiveness has been demonstrated in vivo, showing successful modulation of neural activity and targeted drug release across multiple neurological disease models.
Target Audience
Primary customers are clinical research institutions, neuroscience research laboratories, and pharmaceutical companies developing treatments for neurological disorders who require precise, non-invasive therapeutic delivery and neuromodulation capabilities.
Features
- Dual-mode platform supporting both neuromodulation and targeted drug delivery via focused ultrasound
- Patient-specific treatment planning software that accounts for individual brain anatomy
- In vivo validated technology demonstrating modulation of neural activity and triggered drug release
- Non-invasive therapeutic approach eliminating the need for surgical intervention
- Pipeline addressing multiple neurological disorders including tinnitus, Parkinson's disease, brain cancer, epilepsy, and stroke
- Mathematical modelling and therapeutic optimisation capabilities for treatment parameter refinement